These four stocks have soared in 2016. Here are the reasons and a look at whether there is still time to jump aboard.
Johnson & Johnson is undergoing a transformation in its product portfolio. These three ETFs may benefit if investors are excited about third-quarter results.
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.